Turmeric benefits, now eye drops made with its extracts can treat glaucoma

0

Turmeric has many medicinal properties and is used to treat a number of diseases. Now, a derivative of turmeric could be used in eye drops to treat the early stages of glaucoma – one of the leading causes of blindness, a study has found. Researchers from the Imperial College London and University College London in the UK delivers curcumin, extracted from the yellow spice turmeric, directly to the back of the eye using eye drops, overcoming the challenge of curcumin’s poor solubility.

The study, published in the journal Scientific Reports, showed that the eye drops can reduce the loss of retinal cells in rats, which is known to be an early sign of glaucoma. They are also investigating how the eye drops could be used as a diagnostic tool for a range of conditions.

“Curcumin is an exciting compound that has shown promise at detecting and treating the neurodegeneration implicated in numerous eye and brain conditions from glaucoma to Alzheimer’s disease, so being able to administer it easily in eye drops may end up helping millions of people,” said Francesca Cordeiro, a professor at UCL.

Glaucoma is a group of eye conditions affecting over 60 million people worldwide that leads to irreversible blindness in 1 in 10 cases. The condition mainly involves the loss of retinal ganglion cells, a type of neuron located near the surface of the retina. Stopping the loss of these cells early on has not yet been achieved, so it is a key focus of glaucoma research.

Curcumin has previously been shown to protect retinal ganglion cells when administered orally. For the current study, the researchers were seeking to find a more reliable method to deliver curcumin.

Oral administration is difficult because curcumin has poor solubility, so it does not easily dissolve and get absorbed into the bloodstream, and would require people to take large amounts of tablets (up to 24 a day) that may cause gastrointestinal side effects.

Agencies

NO COMMENTS

LEAVE A REPLY